Skip to content
Search

Latest Stories

Titan PMR aims for 10% market share by end of 2023; set-ups new team to cater pharmacy transfer

Titan PMR, a pioneer of cutting pharmacy technology has set up additional new team of 12 staff to cater for a deluge of independent pharmacists investing in new businesses.

The company is utilising the opportunity that is underway as large chains look to sell off or close their community pharmacies, offering an opportunity for pharmacists looking to provide efficient dispensing and additional services.


In January this year Lloyds Pharmacy, which was bought by a private equity firm in 2022, announced plans to close all its 237 branches inside Sainsbury’s stores over the course of 2023. Currently, more than 5,500 of around 14,000 registered pharmacy premises across the UK are owned by corporates and supermarkets.

Titan PMR – an innovative, cloud-based system which manages end-to-end pharmacy workflow – has become the preferred software platform especially amongst first time buyers who are keen to offer new services to patients. The new team at the Bristol-based company, hired to support this sector, sees its total workforce growing to more than 50 staff.

From last October to January this year, Titan has been installed into 125 new pharmacies, most of which were new pharmacy purchases. The figure is more than double from the same period last year.

Currently four million prescriptions per month are dispensed through Titan which accounts for almost five per cent of the UK prescription market.  The company is looking to double these numbers, reaching 10 per cent of market share, by the end of 2023.

Its new team has been set up specifically to cater for new pharmacy transfers, helping ensure new owners have a fully NHS compliant system on their first day with minimal disruption.

Among the crop of new independent pharmacy owners deploying Titan PMR’s team of experts to help with the transition is Karman Chung. He is the new owner of Lakewood Pharmacy in West Wickham, just outside London in north east Kent. The pharmacy was formerly owned by LloydsPharmacy, before being purchased by Mr Chung in February 2023.

“There are so many things to think about when taking over a new pharmacy,” he said. “There are complex contractual negotiations, taking over the lease of the premises, staff contracts, fitness to practise, GPhC change of ownership, obtaining new NHS codes and setting up new suppliers.

“As if that isn't enough, there is choosing the right technology for the pharmacy, along with the necessary understanding of what is needed to make sure the business can be up and running from day one.

“So I was glad to be supported by a team which could help determine the right hardware, offer support with getting a new broadband and internet service, coordinate with LloydsPharmacy and the NHS to transfer patient information and nominations and, on the take over day, send a trainer to train us and get us through. I’m looking forward to growing the new business and providing much needed clinical services to our patients.”

Tariq Muhammad, CEO of Titan PMR, is a pharmacist who previously built up his own successful chain before setting up Invatech Health, the parent company of Titan in 2014.

“I predicted that 2022 would be the year of the independent,” he said. “It’s been happening, and we are keen to play our part in facilitating the transition from big corporate dominance to more dynamic, independent ownership.

“Technology in pharmacy has lagged behind other sectors but Titan has been a game-changer for the industry and with its unique features, such as artificial intelligence that helps free up pharmacists time, is setting the standard that all other systems are following.

“So our new team are ready to help with the full package of services necessary to create the community pharmacy of the future – from project management to guidance needed on connectivity and hardware.

“We know from experience that a new pharmacy acquisition can be traumatic, like buying a house, where dates often change. Our specialist team understand all the issues and can help turnaround things quickly to minimise business disruption and ensure patient care.

“We will train independent pharmacists and any staff they may have, as well as providing go-live support for the most advance PMR system on the market. We’re there to help lay the foundations of a growing network of independent pharmacies suitable for serving 21st century communities.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less